Macrophage Migration Inhibitory Factor as a Novel Biomarker of Portopulmonary Hypertension

• DOI: 10.1086/688489
• Publication Date: 2016-07-12T14:24:00Z
• Authors: Hilary M. DuBrock; Josanna M. Rodrig...; Barbara L. LeVarge; Michael P. Curry; Paul A. VanderLaan; Zsuzsanna K. Zsen...; Elizabeth Pernicone; Ioana R. Preston; Paul B. Yu; Ivana Nikolic; Dihua Xu; Ravi I. Thadhani; Richard N. Channick; S. Ananth Karumanchi
• Keywords: Portopulmonary hypertension

Portopulmonary hypertension (POPH) is a poorly understood complication of liver disease associated with significant morbidity and mortality. We sought to identify novel biomarkers POPH presence severity. performed prospective, multicenter, case-control study involving patients undergoing right heart catheterization. cases were defined as mean pulmonary arterial pressure (mPAP) ≥25 mmHg vascular resistance (PVR) >240 dynes˙s˙cm-5. Plasma samples collected from the systemic circulation, antibody microarray was used biomarkers. Characterization validation candidate cytokine, macrophage migration inhibitory factor (MIF), using enzyme-linked immunosorbent assay. Continuous variables compared Mann-Whitney U test correlated severity Spearman correlation. MIF levels elevated in both circulation controls (median level [interquartile range] circulation: 46.68 ng/mL [32.31-76.04] vs. 31.19 [26.92-42.17], P = 0.009; 49.59 [35.90-108.80] 37.78 [21.78-45.53], 0.002). In POPH, positively PVR (r 0.58, 0.006) inversely cardiac output -0.57, 0.007). >60 or tricuspid regurgitation gradient >50 had 92% sensitivity specificity for diagnosis positive predictive value 86% negative 96%. promising biomarker portal hypertension.